Drug
Exicorilant
Exicorilant: highest development phase Phase 1/2, developed by Corcept Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Exicorilant NCT03437941 | Phase 1/2 | Metastatic Castration-Resistant Prostate Cancer |
Latest
No recent events.
Follow Exicorilant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.